Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
Zevra Therapeutics (ZVRA) announced it will release its third quarter 2024 financial results and provide a corporate update on November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. ET the same day. The update will include progress on the commercial launches of MIPLYFFA™ and OLPRUVA®, along with updates on clinical stage programs. A webcast replay will be available for 90 days on the company's investor relations website.
Zevra Therapeutics (ZVRA) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 e fornirà un aggiornamento aziendale il 12 novembre 2024, dopo la chiusura del mercato. L'azienda terrà una conference call alle 16:30 ET lo stesso giorno. L'aggiornamento includerà progressi sui lanci commerciali di MIPLYFFA™ e OLPRUVA®, insieme ad aggiornamenti sui programmi clinici in fase di sviluppo. Una registrazione del webcast sarà disponibile per 90 giorni sul sito delle relazioni con gli investitori dell'azienda.
Zevra Therapeutics (ZVRA) anunció que publicará sus resultados financieros del tercer trimestre de 2024 y proporcionará una actualización corporativa el 12 de noviembre de 2024, después del cierre del mercado. La empresa realizará una conferencia telefónica a las 4:30 p.m. ET el mismo día. La actualización incluirá avances en los lanzamientos comerciales de MIPLYFFA™ y OLPRUVA®, junto con actualizaciones sobre programas clínicos. Una repetición de la transmisión estará disponible durante 90 días en el sitio web de relaciones con inversores de la empresa.
Zevra Therapeutics (ZVRA)는 2024년 11월 12일 마감 후 2024년 3분기 재무 결과를 발표하고 기업 업데이트를 제공할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜을 개최할 예정입니다. 이 업데이트에는 MIPLYFFA™ 및 OLPRUVA®의 상업 출시 진행 상황과 임상 단계 프로그램에 대한 업데이트가 포함될 것입니다. 웹캐스트 재생은 회사의 투자자 관계 웹사이트에서 90일 동안 제공됩니다.
Zevra Therapeutics (ZVRA) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 et fournira une mise à jour de l'entreprise le 12 novembre 2024, après la clôture du marché. La société tiendra une conférence téléphonique le même jour à 16 h 30 ET. La mise à jour inclura des progrès sur les lancements commerciaux de MIPLYFFA™ et OLPRUVA®, ainsi que des mises à jour sur les programmes cliniques. Un replay du webinaire sera disponible pendant 90 jours sur le site des relations avec les investisseurs de l'entreprise.
Zevra Therapeutics (ZVRA) hat angekündigt, dass am 12. November 2024 nach Börsenschluss die Finanzergebnisse für das dritte Quartal 2024 veröffentlicht und ein Unternehmensupdate gegeben wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz veranstalten. Das Update wird Fortschritte bei den kommerziellen Produkten MIPLYFFA™ und OLPRUVA® sowie aktuelle Informationen zu klinischen Programmen umfassen. Eine Wiederholung des Webcasts wird für 90 Tage auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
Company will host conference call at 4:30 p.m. ET that day
CELEBRATION, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced it will report third quarter financial results and provide a corporate update on Tuesday, Nov. 12, 2024. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day. The corporate update will include recent progress with the commercial launches of MIPLYFFA™ and OLPRUVA® as well as the Company’s clinical stage programs.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at https://investors.zevra.com/.
To join via telephone, please use the following dial-in information:
- (800) 274-8461 (U.S.)
- +1 (203) 518-9814 (International)
- Conference ID: ZVRAQ324
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page of Zevra’s website at https://investors.zevra.com/.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Expanded access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy, as published on its website. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Cautionary Note Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2023, Zevra’s Quarterly Report for the quarter ended Sept. 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Russo Partners Contact
David Schull
+1 (858) 717-2310
david.schull@russopartnersllc.com
FAQ
When will Zevra Therapeutics (ZVRA) report Q3 2024 earnings?
What time is Zevra Therapeutics (ZVRA) Q3 2024 earnings call?
What products will Zevra Therapeutics (ZVRA) discuss in their Q3 2024 update?
How long will Zevra Therapeutics (ZVRA) Q3 2024 earnings call replay be available?
